These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15814571)

  • 21. Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
    Ruiz ML; Rigalli JP; Arias A; Villanueva S; Banchio C; Vore M; Mottino AD; Catania VA
    Drug Metab Dispos; 2013 Feb; 41(2):275-80. PubMed ID: 23077105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidrug Resistance-Associated Protein 3 Is Responsible for the Efflux Transport of Curcumin Glucuronide from Hepatocytes to the Blood.
    Jia YM; Zhu T; Zhou H; Ji JZ; Tai T; Xie HG
    Drug Metab Dispos; 2020 Oct; 48(10):966-971. PubMed ID: 31900255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).
    Zelcer N; Saeki T; Reid G; Beijnen JH; Borst P
    J Biol Chem; 2001 Dec; 276(49):46400-7. PubMed ID: 11581266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oleanolic acid attenuates obstructive cholestasis in bile duct-ligated mice, possibly via activation of NRF2-MRPs and FXR antagonism.
    Chen P; Li J; Fan X; Zeng H; Deng R; Li D; Huang M; Bi H
    Eur J Pharmacol; 2015 Oct; 765():131-9. PubMed ID: 26297978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene.
    Manautou JE; de Waart DR; Kunne C; Zelcer N; Goedken M; Borst P; Elferink RO
    Hepatology; 2005 Nov; 42(5):1091-8. PubMed ID: 16250050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor.
    Cherrington NJ; Slitt AL; Maher JM; Zhang XX; Zhang J; Huang W; Wan YJ; Moore DD; Klaassen CD
    Drug Metab Dispos; 2003 Nov; 31(11):1315-9. PubMed ID: 14570762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
    Vlaming ML; Mohrmann K; Wagenaar E; de Waart DR; Elferink RP; Lagas JS; van Tellingen O; Vainchtein LD; Rosing H; Beijnen JH; Schellens JH; Schinkel AH
    J Pharmacol Exp Ther; 2006 Jul; 318(1):319-27. PubMed ID: 16611851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3).
    Lee YM; Cui Y; König J; Risch A; Jäger B; Drings P; Bartsch H; Keppler D; Nies AT
    Pharmacogenetics; 2004 Apr; 14(4):213-23. PubMed ID: 15083066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholestasis and the role of basolateral efflux pumps.
    Keppler D
    Z Gastroenterol; 2011 Jul; 49(12):1553-7. PubMed ID: 22139880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.
    Vlaming ML; Pala Z; van Esch A; Wagenaar E; van Tellingen O; de Waart DR; Oude Elferink RP; van de Wetering K; Schinkel AH
    Clin Cancer Res; 2008 Dec; 14(24):8152-60. PubMed ID: 19088030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue distribution and induction of human multidrug resistant protein 3.
    Scheffer GL; Kool M; de Haas M; de Vree JM; Pijnenborg AC; Bosman DK; Elferink RP; van der Valk P; Borst P; Scheper RJ
    Lab Invest; 2002 Feb; 82(2):193-201. PubMed ID: 11850532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bile salt transporters.
    Meier PJ; Stieger B
    Annu Rev Physiol; 2002; 64():635-61. PubMed ID: 11826283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
    Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
    Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of bile acids on the expression of MRP3 and MRP4: An In vitro study in HepG2 cell line.
    Pérez-Pineda SI; Baylón-Pacheco L; Espíritu-Gordillo P; Tsutsumi V; Rosales-Encina JL
    Ann Hepatol; 2021; 24():100325. PubMed ID: 33582321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53-mediated regulation of bile acid disposition attenuates cholic acid-induced cholestasis in mice.
    Chen P; Li D; Chen Y; Sun J; Fu K; Guan L; Zhang H; Jiang Y; Li X; Zeng X; Chen X; Huang M; Bi H
    Br J Pharmacol; 2017 Dec; 174(23):4345-4361. PubMed ID: 28910492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial characterization of cytoprotective mechanisms of lecithin against bile salt-induced bile duct damage.
    Tsuboi K; Tazuma S; Nishioka T; Chayama K
    J Gastroenterol; 2004 Oct; 39(10):955-60. PubMed ID: 15549448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation.
    Jang JH; Rickenbacher A; Humar B; Weber A; Raptis DA; Lehmann K; Stieger B; Moritz W; Soll C; Georgiev P; Fischer D; Laczko E; Graf R; Clavien PA
    Hepatology; 2012 Jul; 56(1):209-18. PubMed ID: 22290718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.
    Chen W; Cai SY; Xu S; Denson LA; Soroka CJ; Boyer JL
    Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1221-7. PubMed ID: 17272513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes.
    Tian X; Zamek-Gliszczynski MJ; Zhang P; Brouwer KL
    Mol Pharmacol; 2004 Oct; 66(4):1004-10. PubMed ID: 15385645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of farnesoid X receptor inhibition in obstructive cholestasis.
    Stedman C; Liddle C; Coulter S; Sonoda J; Alvarez JG; Evans RM; Downes M
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11323-8. PubMed ID: 16844773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.